Pipeline

Innovation is in GenSci's DNA. GenSci advances a robust, innovative portfolio across four therapeutic areas: endocrinology & metabolism, women's health, immunology & respiratory diseases, and oncology.

The pipeline is updated quarterly. Last updated December 2025.
The pipeline is approved in at least one major market, such as China, USA and/or EU.
Only selected pipeline molecules are presented here.

Oncology Pipeline

Molecule

Indication(s)

Target(s)

IND

Phase Ⅰ

Phase Ⅱ

Phase Ⅲ

Registration

Launch

Medroxy-
progesterone Acetate

Anorexia-cachexia Syndrome

PR (Progesterone Receptor)

Medroxy-
progesterone Acetate

CINV

PR (Progesterone Receptor)

GenSci143

mCRPC

B7-H3 x PSMA(ADC)

GenSci139

UC, NSCLC

EGFR x HER2(ADC)

GenSci128

Solid Tumors

P53 Y220C

GenSci140

OVC

FRα(ADC)

GenSci153

Prostate Cancer

PSMA

Oncology Pipeline

- IND
- Phase Ⅰ
- Phase Ⅱ
- Phase Ⅲ
- Registration
- Launch
- Medroxy-
  progesterone Acetate
  
  Anorexia-cachexia Syndrome
  
  PR (Progesterone Receptor)
- Medroxy-
  progesterone Acetate
  
  CINV
  
  PR (Progesterone Receptor)
- GenSci143
  
  mCRPC
  
  B7-H3 x PSMA(ADC)
- GenSci139
  
  UC, NSCLC
  
  EGFR x HER2(ADC)
- GenSci128
  
  Solid Tumors
  
  P53 Y220C
- GenSci140
  
  OVC
  
  FRα(ADC)
- GenSci153
  
  Prostate Cancer
  
  PSMA